Ozempic and Wegovy have received a lot of publicity as revolutionizing treatment options for obesity. Both medications form a class of GLP-1 receptor agonists, which mimic a hormone in the body called glucagon-like peptide-1 and are involved in the regulation of appetite and blood sugar. Indeed, in initial clinical studies, the majority of those on the drugs lost 15% to 22% of body weight, hence much optimism. For most patients, these medications are underwhelming for about 20% of patients due to minimal weight loss or other challenges.

Take a closer look at why the weight loss drugs may not work for everyone, together with what options exist when they don't deliver the expected outcomes.

Why Weight Loss Drugs May Not Work

While GLP-1 receptor agonists have produced phenomenal responses in a majority of patients, it remains a reality that these drugs work differently for different people. Here's why:

1. Genetic and Hormonal Variability

Weight loss medications interact with complex systems in the body that differ from person to person. Genetics, hormones, and individual brain responses to energy regulation play significant roles in determining how a person responds to drugs like Ozempic and Wegovy.

2. Underlying Medical Conditions

Other conditions, such as sleep apnea, may be prevalent and prevent or delay the achievement of weight loss goals. Prescription drugs like antidepressants, steroids, or contraceptives are other medications that can nullify weight loss medication benefits.

3. Unrealistic Expectations

Often, they come to these medications with enormous hopes; expecting the promised rapid and dramatic weight loss. Progress creates disappointment if it has not stalled. In patients who rigidly follow recommended lifestyle modifications, frustration and disappointment are most common.

Why it is Important to Identify Non-responders

For most patients, the effectiveness of GLP-1 receptor agonists is evident within a few weeks of treatment. Weight loss typically begins within a few weeks of initiating therapy and tends to increase with dosage. However, some patients respond very little, if at all, despite strict adherence to their regimen.

For nonresponders, this can feel like a dead end. However, understanding the unique complexities of obesity is essential. This condition stems from brain dysfunction, and the pathways that contribute to weight regulation differ among individuals.

Alternative Treatment Options

When Ozempic or Wegovy doesn’t yield desired results, there are still many paths to explore:

1. Switching to Another GLP-1 Drug

For example, some patients who don't respond well to one GLP-1 receptor agonist might find success with another drug in the same class. Newer medications, such as Zepbound, target other hormone pathways and seem promising even for those not responsive to earlier drugs.

2. Use of Older Medications

While there is much to say about newer drugs, older treatments can still be useful and work for some patients. One can also seek the help of a medical provider specializing in obesity treatments in order to identify the best alternatives.

3. Lifestyle Changes

Diet, exercise, sleep, and stress management continue to be integral components of any weight loss program. New changes may be small but can make an enormous difference in one's health and success.

4. Medical Management of Obesity

It is a complex disorder, and most patients should receive a multidisciplinary treatment. Collaboration with an obesity-aware doctor may mean access to tailored treatment plans, ranging from psychological support all the way to metabolic testing, and many others.

Why Side Effects of Weight Loss Drug Ozempic May Be a Barrier

For others, side effects like nausea, vomiting, or diarrhea hinder them from continuing with these drugs. These symptoms often reduce as the body becomes accustomed, but for some, they might be severe enough to stop treatment altogether. In those instances, alternative drugs or procedures become vital to find.

Long-term effects of Ozempic or Wegovy on the Brain

Another largely unexplored area relates to GLP-1 drugs' long-term effects on the brain's regulation of hunger and satiety. Although GLP-1 drugs suppress appetite and can lead to effective weight loss, emerging research suggests that they may also affect brain reward mechanisms, changing the way patients experience foods.

This aspect could prove of paramount significance in the future treatment of obesity. Perhaps GLP-1 receptor agonists do indeed affect and rewire the brain's reward pathways and will thus provide sustained benefits beyond discontinuation. However, more research is required to understand this phenomenon fully.

While for many, Ozempic and Wegovy have revolutionized obesity treatment, these are certainly not a one size fits all. Nonresponders need not lose hope- alternative strategies and medications abound. A consultation with an obesity expert healthcare provider is essential to put together a comprehensive, tailored treatment plan.

The route toward effective weight loss may be challenging, but with the evolution of obesity medicine and a better understanding of individual needs, there is a path forward for everyone.

"I'm not scared of a germ, I used to snort cocaine off of toilet seats," said the US Secretary of Health and Human Services Robert F Kennedy Jr. Now 72, he said during a Theo Von podcast that he continued with in-person rehab meeting during pandemic due to his addiction because of his robust approach to infection.

In a statement, he said, "I said, ‘I don’t care what happens, I’m going to a meeting every day’,” he told Von. “I said, ‘I’m not scared of a germ — I used to snort cocaine off of toilet seats — and I know this disease [addiction] will kill me if I don’t treat it, which means, for me, going to meetings every day … for me, it was survival.”

Read: RFK Jr. Removes Entire CDC Vaccine Advisory Committee

What Is Wrong With RFK Jr's Statement?

While toilet seat may not be the dirtiest item in an average household, as scientists, including professor of microbiology at the University of Arizona, Dr Chuck Gerba told BBC that there are other dirtier items too. The statement to snort off a toilet seat could have a wrong tone.

While there exist other items with more bacteria than toilet, it is no safe to snort things off toilet seat and absolutely not to do drugs and to brag about it. This feels especially off when it comes from a Health Secretary.

On an average, a toilet seat typically has around 50 to 3,000 bacteria per square inch. A toilet seat could have many bacteria, including E. coli, Salmonella, norovirus and Shigella. They can cause gastrointestinal distress.

What is wrong with RFK Jr.'s statement is that having frequent encounters with fecal bacteria will not scientifically make him immune against the respiratory viruses which were common during the COVID-19 pandemic.

Read: Who is Robert F. Kennedy Jr., the Controversial Nominee for U.S. Health Secretary?

This is because bacteria are single-celled, living organisms that can live independently, while viruses are much smaller, non-living agents and require a host cell to reproduce. The basic difference in its composition and how they function after entering the body is the reason why exposure to bacteria does not necessarily means one is protected or has immunity against a virus.

RFK Jr And His Anti-Vaxxer Stance

He is the nephew of former US President John F Kennedy popularly known as JFK, who was a democratic candidate. However, RFK Jr., who earlier filed candidature as a Democrat, then switched to an independent candidate and endorsed Trump heavily.

RFK Jr. works closely with many anti-vaccine activists who work for his nonprofit group Children's Health Defense. While in his recent speech, he said that he has "never been anti-vax and have never told the public to avoid vaccination", his track record shows otherwise.

In a podcast interview, he said, "There is no vaccine that is safe and effective" and told FOX News that he still believes in the now long-debunked idea that vaccines can cause autism. In another 2021 podcast, he urged people to "resist" CDC guidelines on getting their kids vaccinated. "I see somebody on a hiking trail carrying a little baby and I say to him, better not get them vaccinated," he said.

His non-profit also led an anti-vax campaign sticker and he appeared next on the screen to a sticker that read: "If you are not an anti-vaxxer you are not paying attention," reports AP.

Five weeks after the launch of Novo Nordisk's weight loss pill, Wegovy, 38,220 US prescriptions have been reported by IQVIA for the same. The company shares too climbed up by 4% on Friday, and touched the levels last seen in October.

The oral version of the Wegovy pill became available to US patients earlier this month after the US Food and Drug Administration (FDA) approved it in December.

How Effective Is The Wegovy Pill?

After injection by Novo Nordisk, of the same name, Wegovy, which has been on the market since 2021, its popularity grew so much that it was in short supply until February 2025. The pill version has now come out, which many experts believe will expand its accessibility. As the monthly supply of pill is expected to be cheaper than the monthly supply of the weight loss injection.

A study published in the New England Journal of Medicine show that a 25 milligram Wegovy pill led to 13.6% reduction in weight on average over 64 weeks. When compared to placebo, the result was only 2.2% of weight loss. Novo Nordisk says that those who stayed on the treatment and reduced their calorie intake, it would lead to a loss of 16.6% of their weight.

How To Use The Weight Loss Pill?

The first step lies in buying the correct and safe weight loss pill. Make sure the weight loss pills are clinically proven option for people to use to reduce their weight.

Take the pill with a glass of water. Make sure to always have the pill prescribed and follow the instructions that you GP has told. Store the pill in a cold place, however avoid freezing the medicine. Keep the medicine out of a child's reach. In some weight loss pills, if you miss your dosage, you can take it within 1 hour, however, clarify these doubts from your GP. A pill can usually be consumed within an hour of a fat-containing meal up to three times a day., however, the Wegovy pill must be taken on an empty stomach. Patients are advised not to eat, drink, or take other medicines for at least 30 minutes afterward. Thus, one must follow what is being prescribed for the best result, as the administering of the pill could vary based on the medication.

Most importantly, a healthy balanced diet, and a regular workout routine is also important will the person is on the pill.

Read: Wegovy Starter Dose Now Available As Daily Pill, Replacing Weekly Injections

What Are The Side Effects Of Wegovy Pill?

Digestive problems such as nausea and vomiting remain the most common side effects of GLP-1 drugs. These issues were also reported in studies of the pill versions. Around 7 percent of participants taking the Wegovy pill stopped treatment because of side effects, compared with 6 percent in the placebo group. In orforglipron’s trial, up to 10 percent of patients discontinued treatment, compared with 3 percent on placebo.

One key difference lies in how the medications are used. The Wegovy pill must be taken on an empty stomach with a small amount of water. Patients are advised not to eat, drink, or take other medicines for at least 30 minutes afterward. Doctors say this requirement has limited the use of Rybelsus, the pill form of semaglutide approved for diabetes, compared with Ozempic.

Eli Lilly highlights that orforglipron was taken once daily in trials without restrictions on food or water, which may make it easier for patients to use consistently.

On February 13, Canadians across the country mark Wear Red Canada Day, a reminder that heart disease remains the leading cause of death for women. Yet despite the scale of the problem, many women still do not recognize their risk or their symptoms.

“We’re learning more and more each day about how heart disease uniquely affects women,” said nurse practitioner and researcher Rachel Ollivier in an interview with CTV News. She emphasized that awareness is still lagging, both among patients and within health-care systems.

According to the World Health Organization, cardiovascular disease accounts for roughly one in three deaths among women globally. In Canada, heart disease and stroke continue to be leading causes of death among women, and women are less likely than men to receive timely diagnosis or treatment.

Symptoms Can Look Different

Chest pain remains the most common heart attack symptom in both men and women. But Ollivier explained that women’s symptoms can often be subtler or feel different.

“For women, they often uniquely experience chest pain that seems like more of a discomfort or a tightness in the chest,” she said. Some women may feel pain in the left arm or jaw, unusual fatigue, nausea, vomiting, or discomfort between the shoulder blades.

Because these symptoms can be less specific, they are sometimes dismissed as stress, anxiety, indigestion, or exhaustion. Social factors also play a role. Women often juggle multiple responsibilities at home and work, and may delay seeking care. In some cases, their concerns may also be minimized within health-care settings.

Medical differences matter too. Women typically have smaller hearts and arteries, and plaque buildup behaves differently compared to men. Conditions such as spontaneous coronary artery dissection and microvascular dysfunction are seen more commonly in women, making diagnosis more complex.

Hormones and the Hidden Risk Window

Beyond symptoms, experts are urging greater recognition of the role hormones play in lifelong heart health.

“Endogenous estrogen is cardio protective,” Ollivier explained. As women enter the perimenopausal transition, estrogen levels fluctuate and gradually decline, and that protection is lost. This shift can lead to higher cholesterol levels and changes in fat distribution, increasing cardiovascular risk, particularly between the ages of 40 and 60.

Colleen Norris, a nursing professor at the University of Alberta and research lead of the CKHui LHHW Women’s Heart Health Research Collaborative who wrote on Yahoo Canada, believes the conversation needs to go even deeper.

She argues that ovaries have long been viewed only through the lens of reproduction. “The ovaries are not just reproductive organs. They are architects of women’s health across the lifespan,” she noted. Estrogen influences the heart and blood vessels, but also the brain, bones, kidneys, metabolism, and immune function.

Most women are never told that ovarian reserve and estrogen levels begin declining in their late 30s. By the time noticeable symptoms appear, biological changes may have already been underway for years.

Menopause itself is just one day, Norris explained. The larger reproductive transition surrounding it is what significantly increases vulnerability to chronic disease. Yet the health-care system often waits until disease develops before intervening.

Moving From Awareness to Action

Both experts stress that education is critical. Women with conditions such as polycystic ovary syndrome, pregnancy complications like preeclampsia or gestational diabetes, and those entering midlife should be particularly mindful of their cardiovascular risk.

Wear Red Canada Day is meant to spark awareness, but symbols alone are not enough. Experts are calling for better research funding focused on midlife women, improved medical education around ovarian aging, and more proactive screening during the reproductive transition.

Heart disease in women is not inevitable. But recognizing that symptoms can differ, and that hormonal shifts matter, could be lifesaving.